Volume 11, Number 6—June 2005
Research
Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance
Table 3
Proportion of erythromycin-resistant Streptococcus pneumoniae isolates collected from years 1 to 3 of the PROTEKT US study that exhibit the dual mef(A)+erm(B) genotype according to source of isolate*
Source of isolate | No. erm(B)+mef(A)–positive/no. erythromycin-resistant (%) |
||
---|---|---|---|
Year 1 | Year 2 | Year 3 | |
BAL | 35/346 (10.1) | 47/349 (13.5) | 74/426 (17.4) |
Blood | 24/805 (3.0) | 31/568 (5.5) | 37/641 (5.8) |
CSF | – | 1/2 (50.0) | – |
Ear | 67/420 (16.0) | 48/246 (19.5) | 107/354 (30.1) |
Eye | 3/16 (18.8) | 11/120 (9.2) | 2/7 (28.6) |
MEF | 2/34 (5.9) | 6/29 (20.7) | 14/40 (35.0) |
NAP | 34/246 (13.8) | 43/242 (17.8) | 51/235 (21.7) |
Sinus | 18/162 (11.1) | 15/159 (9.4) | 36/180 (20.0) |
Sputum | 117/1,056 (11.1) | 129/1,050 (12.3) | 199/1,294 (15.4) |
Throat | 1/15 (6.7) | 1/8 (12.5) | – |
Not specified | 3/33 (9.1) | 3/20 (15.0) | – |
Total | 304/3,133 (9.7) | 335/2,793 (12.0) | 520/3,177 (16.4) |
*BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; MEF, middle-ear fluid; NAP, nasopharyngeal swab or aspirate; –, no isolates collected.